Literature DB >> 16446850

[Cerebrovascular disease in a Neurologic Intermediate Care Unit in Chile. Analysis of 459 consecutive patients].

Patricio Mellado T1, Jaime Court L, Jaime Godoy F, Victoria Mery C, Carolina Barnett T, Max Andresen H, Isidro Huete L, José Tevah C, Vinko Tomicic F, Carlos Romero P, Ricardo Fadic R, Marco A Soza M, Raúl Valenzuela M, Jorge Tapia I.   

Abstract

BACKGROUND: Stroke is the second cause of mortality and the first cause of morbidity in Chile and worldwide. Nowadays there is a major interest in introducing new therapies applying evidence based medicine for these patients. AIM: To describe the clinical profile of patients attended after a stroke, to determine stroke subtypes and their risk factors.
MATERIAL AND METHODS: Retrospective review of clinical records of 459 patients (mean age 65+/-48 years, 238 female) that were admitted to our unit during a period of 37 months.
RESULTS: Sixty three percent of patients had an ischemic stroke, 14% had an hemorrhagic stroke, 15% had a transient ischemic attack, 2% had a cerebral venous thrombosis and 6% a subarachnoidal hemorrhage. The global mortality was 1%. Seventy percent of patients had a history of high blood pressure.
CONCLUSIONS: The most common type of stroke is ischemic and high blood pressure is the main risk factor.

Entities:  

Mesh:

Year:  2005        PMID: 16446850     DOI: 10.4067/s0034-98872005001100002

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  IL-17A Enhances Microglial Response to OGD by Regulating p53 and PI3K/Akt Pathways with Involvement of ROS/HMGB1.

Authors:  Bin Zhang; Ning Yang; Zhi-Ming Mo; Shao-Peng Lin; Feng Zhang
Journal:  Front Mol Neurosci       Date:  2017-08-31       Impact factor: 5.639

2.  Establishing a model of middle cerebral artery occlusion in rabbits using endovascular interventional techniques.

Authors:  Lei Feng; Jun Liu; Jian Chen; Li Pan; Guang Feng
Journal:  Exp Ther Med       Date:  2013-08-05       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.